InspireMD

InspireMD Financial Leverage

The Financial Leverage (Equity Multiplier) of InspireMD (NSPR) as of Oct 16, 2026 is 1.26. In the previous year, Financial Leverage (Equity Multiplier) was 1.30 — a change of -3.07% (lower).

Financial Leverage

1.26

YoY

-3.07%

Last updated:

Financial Leverage (Equity Multiplier) of InspireMD is 2025 1.26 . Financial Leverage (Equity Multiplier) of InspireMD was 2024 1.30 . It decreases by -3.07% lower compared to the previous year.

The InspireMD Financial Leverage history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Financial Leverage
Date
Financial Leverage
Jan 1, 2018
1.40 USD
Jan 1, 2019
1.84 USD
Jan 1, 2020
1.46 USD
Jan 1, 2021
1.18 USD
Jan 1, 2022
1.42 USD
Jan 1, 2023
1.21 USD
Jan 1, 2024
1.30 USD
Jan 1, 2025
1.26 USD
The InspireMD Financial Leverage history
YEARFinancial LeverageYoY
1.26-3.07%
1.30+7.54%
1.21-14.91%
1.42+19.68%
1.18-18.97%
1.46-20.37%
1.84+30.89%
1.40-37.38%
2.24-3.73%
2.33-218.61%
-1.96-52.30%
-4.11—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

InspireMD Stock analysis

What does InspireMD do? InspireMD Inc, listed on the stock market with ticker NSPR and ISIN US45779A8466, is a medical device company based in Tel Aviv-Yafo, Israel. The company operates within the Health Care sector, specifically in the Health Care industry. InspireMD has 127 employees and went public through an IPO on April 12, 2013. Its website is http://www.inspiremd.com/. The company focuses on developing and commercializing stent platform technology for treating complex vascular and coronary diseases. InspireMD's MicroNet is a micron mesh sleeve designed to wrap around a stent, providing embolic protection during stenting procedures. The company also offers the CGuard carotid embolic prevention system, which integrates MicroNet with a self-expandable nitinol stent for carotid artery applications. Additionally, InspireMD markets the MGuard Prime Embolic Protection System, a bare-metal cobalt-chromium stent, for coronary disease treatment in the European Union. The MGuard Prime EPS is also intended for use in patients with acute coronary syndromes, including acute myocardial infarction and saphenous vein graft coronary interventions. The company is developing a neurovascular flow diverter called NGuard, an endovascular device. InspireMD's technology aims to enhance safety and efficacy in vascular and coronary interventions by preventing embolic events during stent placement. InspireMD is one of the most popular companies on Eulerpool.

Frequently Asked Questions about InspireMD stock

Financial Leverage (Equity Multiplier) of InspireMD is 1.26 in 2025.

Financial Leverage (Equity Multiplier) of InspireMD changed from 1.30 to 1.26, representing a -3.07% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Financial Leverage (Equity Multiplier) InspireMD since 2006 – with annual values, charts, and detailed analysis.

Financial leverage, also known as the equity multiplier, measures total assets relative to equity. Higher leverage amplifies both returns and risks.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Financial Leverage (Equity Multiplier)'s InspireMD with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — InspireMD

All Key Metrics — InspireMD